Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P30049
UPID:
ATPD_HUMAN
Alternative names:
ATP synthase F1 subunit delta; F-ATPase delta subunit
Alternative UPACC:
P30049; D6W5Y3; Q6FG90
Background:
ATP synthase subunit delta, mitochondrial, also known as ATP synthase F1 subunit delta or F-ATPase delta subunit, plays a pivotal role in cellular energy production. It is a crucial component of the mitochondrial membrane ATP synthase (Complex V), which generates ATP from ADP, utilizing a proton gradient created by the respiratory chain. This process is essential for a wide range of cellular functions and energy-dependent processes.
Therapeutic significance:
The protein is linked to Mitochondrial complex V deficiency, nuclear type 5, a disorder marked by metabolic decompensation, developmental delay, and 3-methylglutaconic aciduria. Understanding the role of ATP synthase subunit delta, mitochondrial could open doors to potential therapeutic strategies for this and related mitochondrial disorders.